Compare Biogen Inc (BIIB) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs NextEra Energy, Inc. — how do they compare? Biogen Inc trades at $196.1 (market cap $28.34B), while NextEra Energy, Inc. trades at $88.76 (market cap $186.75B). The key difference: NextEra Energy, Inc. is far larger — about 6.6× Biogen Inc's market cap, and NextEra Energy, Inc. pays a 2.78% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NEE | |
|---|---|---|
Market Cap | $28.34B | $186.75B |
Sector | Health | Utilities |
52-Week High | $216.63 | $97.88 |
52-Week Low | $122.68 | $69.77 |
Enterprise Value | $30.62B | $289.15B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
NextEra Energy (NEE) trades at $88.38, up 0.48% with neutral technical signals. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though revenue growth has been volatile. Recent earnings beat expectations in Q1 2026, with Q2 results due July 24. Analyst consensus is strongly bullish with $103 price target, while technical indicators show RSI at neutral levels with support at $87-88.
NEE presents a compelling utility investment with clean energy leadership and dividend growth potential, though faces risks from capital expenditure demands and regulatory uncertainty. The stock trades below analyst targets with institutional support, but investors should monitor execution on the Dominion deal and AI-driven power demand trends that could impact future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
